|
||
J. Exp. Med.,
Volume 189, Number 12, June 21, 1999 1885-1894
By
From the Department of Allergy and Clinical Immunology, National Heart and Lung Institute,
Imperial College School of Medicine, London SW3 6LY, United Kingdom
Intradermal administration of short overlapping peptides derived from chain 1 of the cat allergen Fel d 1 (FC1P) that did not cross-link IgE, elicited isolated late asthmatic reactions with no
visible early or late cutaneous response in 9/40 cat-allergic asthmatics. Four of the nine were
human histocompatibility leukocyte antigen DR13-positive, as compared with only 1/31 nonreactors. The other five reactors expressed either DR1 or DR4. To confirm major histocompatibility complex restriction, fibroblast cell lines transfected with HLA-DR molecules were
used to present FC1Ps to cat allergen-specific T cell lines derived from subjects before peptide injection. FC1P3 (peptide 28-44 of Fel d 1 chain 1) was recognized in the context of DR13 alleles
(DRB1*1301, 1302) and induced specific T cell proliferation and IL-5 production. T cells from a
DR1+ responder proliferated and produced IL-5 in the presence of FC1P3 and DR1
(DRB1*0101) fibroblast cell lines, whereas T cells from a DR4+ subject recognized FC1P2 (peptide 22-37) when presented by DRB1*0405. We conclude that short, allergen-derived peptides
can directly initiate a major histocompatibility complex-restricted, T cell-dependent late asthmatic reaction, without the requirement for an early IgE/mast cell-dependent response, in sensitized asthmatic subjects.
This article has been cited by other articles:
| TABLE OF CONTENTS |
|